CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 249 enrolled
Drug / intervention
No nameother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00636467
NCT00636467Phase 2Completed

Evaluation of the Technique of Axillary Sentinel Lymph Node (SLN) Detection in Breast Cancers > 2 cm

Centre Leon Berard·interventional·Posted Mar 14, 2008·Updated Sep 26, 2012

In Brief

A Phase 2 clinical trial evaluating No name for Breast Cancer. Completed, enrolled 249 participants across 22 sites.

Detailed Summary

The purpose of this study is to evaluate the quality criteria of the SLN detection technique in breast cancer patients with a tumor size (clinical measurement) greater than 2 centimeters (rate of false negatives, rate of detection). Eligible patients will only be registered (no randomization). The estimated inclusion period is approximately 24 months. The duration of the research is 25 months (24 months for patient inclusion + 1 month for reception of results). The maximum participation duration of each patient is 1 month. The number of patients required in this multicentric and prospective study is 240 (16 participating centers).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesFrance

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 14, 2008
Enrollment StartMar 1, 2008
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.3 years ago

Interventions

No nameother

Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)